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Abstract
In eukaryotic cells, control mechanisms have developed that restrain cell-cycle transitions in
response to stress. These regulatory pathways are termed cell-cycle checkpoints. The G2/M
checkpoint prevents cells from entering mitosis when DNA is damaged in order to afford these
cells an opportunity to repair the damaged DNA before propagating genetic defects to the
daughter cells. If the damage is irreparable, checkpoint signaling might activate pathways that lead
to apoptosis. Since alteration of cell-cycle control is a hallmark of tumorigenesis, cell-cycle
regulators represent potential targets for therapy. The centrosome has recently come into focus
as a critical cellular organelle that integrates G2/M checkpoint control and repairs signals in
response to DNA damage. A growing number of G2/M checkpoint regulators have been found in
the centrosome, suggesting that centrosome has an important role in G2/M checkpoint function. In
this review, we discuss centrosome-associated regulators of the G2/M checkpoint, the
dysregulation of this checkpoint in cancer, and potential candidate targets for cancer therapy.
Introduction
With the aging of the world's population, the westerniza-
tion of diet, and the increasing environmental pollution
associated with the global economy, cancer has emerged
as the top threat to human life worldwide [1,2]. To
advance our progress against this disease, the two most
important goals for cancer researchers are to fully under-
stand the molecular basis of cancer and to develop effec-
tive therapies for it. One of the hallmarks of
carcinogenesis is dysregulation of the cell cycle [3]. Cell
cycle is controlled at a number of checkpoints. When cells
suffer extracellular or intracellular stress or both, the cell-
cycle checkpoints, especially G1/S and G2/M checkpoints
which are controlled by a number of complexes that are
composed of cyclin-dependent kinases (Cdks), cyclins,
and their negative regulators including the Cip/Kip family
members and the INK4a/ARF family members [4-6], are
activated. The G1/S checkpoint is the first surveillance sys-
tem to stop DNA synthesis when cells suffer from extracel-
lular stresses and it is an effective step to control cell
proliferation and apoptosis. The mechanism of G1/S
checkpoint is extensively studied [5-8]. The G2/M check-
point prevents DNA-damaged cells from entering mitosis
and allows for the repair of DNA that was damaged in late
S or G2 phases prior to mitosis. The G2/M checkpoint is
controlled by Cdc2/cyclinB, and their negative regulators
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including p21Cip1 and p27 [9]. Weakened G2/M check-
point under therapeutic setting may trigger cell death via
mitotic catastrophe for cells with unrepairable DNA
lesions and mitosis machinery. This may represent a novel
strategy to kill cancer cells, especially those with the p53
mutant phenotype which could result in inactivation or
lost of the G1/S checkpoint in cancer [10,11]. Thus, the
G2/M checkpoint is a potential target for cancer therapy.
As the primary microtubule-organizing center (MTOC),
the centrosome plays an important role in maintaining
chromosome stability by establishing bipolar mitotic
spindles. Accumulating evidence suggests that centro-
some integrates cell-cycle arrest and repair signals in
response to genotoxic stress [12]. A growing number of
important cell cycle regulators such as Cdks, checkpoint
kinases (Chks), polo-like kinases (Plks), Aurora kinases,
NIMA-related kinases (Neks), p53, BRCA1, and cyclin B1
have been shown to localize to the centrosome (Table 1).
All of those proteins have been implicated in participating
in G2/M checkpoint control and in the regulation of cen-
trosome separation [13-20]. Abnormal expression (either
under or over) of these proteins has been observed in
most cancers [21] and they have been found to directly
influence the efficacy of antitumor agents [22]. Thus,
manipulating these G2/M checkpoint proteins could
enhance cancer's sensitivity to radiotherapy and chemo-
therapy. In this review we focus on centrosome-associated
regulators of G2/M checkpoint and potential targets for
cancer chemotherapeutic therapy.
Cell cycle and centrosomal cycle
The cell cycle entails a recurring sequence of events that
include the duplication of cellular contents and subse-
quent cell division. Traditionally, the cell cycle in the
eukaryotic cell is divided into four phases: Gap phase 1
(G1); DNA synthesis phase (S); Gap phase 2 (G2), during
which the cell prepares itself for division; and mitosis
phase (M), during which the chromosomes separate and
the cell divides. The M phase includes prophase, met-
aphase, anaphase, and telophase [23].
Centrosome, the nonmembranous organelles that occupy
a tiny volume near the center of the cell, are usually prox-
imal to the nucleus. In most vertebrate cells, the centro-
some is classically depicted as having two orthogonally
positioned cylindrical centrioles surrounded by a matrix
of fibrous and globular proteins that constitute the peri-
centriolar material (PCM)[24]. The cell cycle involves an
intricate process of DNA replication and cell division that
concludes with the formation of two genetically equiva-
lent daughter cells. In this progression, the centrosome is
duplicated only once to produce the bipolar spindle and
ensure proper chromosome segregation. Centrosome
maturation and separation are tightly regulated during the
cell cycle. Centrosome duplication consists of the five
morphological steps during cell cycle progression [25]. 1)
In early G1/S phase, the mother and daughter centrioles
separate slightly and lose their orthogonal orientation; 2)
in S phase, synthesis of a daughter centriole occurs in the
vicinity of each preexisting centriole; 3) in G2 phase, the
procentrioles elongate to complete the duplication proc-
Table 1: Centrosome-associated G2/M checkpoint proteins
Centrosome proteins Substrates Functions Effects of expression manipulation
cyclin B/Cdk1 [33] Drp1/Dnml1, HuR, hnRNP-k, TPX2 mitosis entry, bipolar spindle assembly inhibition: induce cell cycle arrest and 
apoptosis
Aurora A[34,35,76] centrosomin, γ-TuRC, Eg5, Ran-TPX2, 
CENP-A, PP1, p53, Cdh1, NM23-H1, 
CPEB, Cdc25B, TPX2
mitotic entry and exit, centrosome 
mutation and separation, spindle 
formation
inhibition: monopolar spindle 
overexpression: centrosome 
amplification and loss of mitotic 
checkpoint
Aurora B[34,35] INCEP, Survivin, BubR1, Mad2 chromatid separation, spindle 
assembly checkpoint
inhibition: multinucleate cells
Plk1[21,34,36] Cdc25, cyclinB/Cdk1, p53, Nlp1, ATM/
ATR, BRCA1, Chk1, Emi1, Wee1
mitotic entry and exit, APC/C 
regulation, bipolar spindle formation, 
centrosome maturation,
inhibition: smaller centrosomes
Nek2A[18,34,101] PP1, C-Nap1 centrosome separation and 
maturation, mitotic entry
overexpression: split centrosomes
Survivin[90,91,102] Caspases 3, 7, 9, Aurora B, INCENP anti-apoptosis inhibition: loss of mitotic kinases and 
checkpoint, supernumerary centrosome
p53[47,48] p21, 14-3-3, GADD45 centrosome duplication inhibition: centrosome amplication
BRCA1[51,52] γ-Tubulin, Chk1/2, p53, Cdc25, Wee1, 
Aurora A
centrosome duplication inhibition: centrosome re-duplication 
and hyperactive MT nucleation
APC/C[99] Cyclin B/Cdk1, securin, Aurora A, Plk1, 
Cdk2
sister chromatid separation, mitotic 
exit, proteasomal degradation
NA
ATM/ATR[55] p53, Chk1/2, BRCA1, Mdm2 initiation of genotoxic stress response NA
Chk1/2 [56-59] Cdc25, BRCA1, E2F, p73α centrosome separation, mitotic entry inhibition: centrosome amplification and 
mitotic arrestMolecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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ess. The duplicated centrosome disjoins into two func-
tionally separate centrosome, each containing a mother-
daughter pair of centrioles; 4) in late G2 phase, the centro-
some increases in size and separate to allow the formation
of a bipolar spindle; 5) in M phase, the original mother
and daughter centrioles detach from each other in an
event termed centrosome disjunction. Since centrosome
duplicates only once during the normal cell cycle, dupli-
cation of centrosome must proceed in coordination with
DNA synthesis to synchronize with cell division [26].
Centrosome appears to be a critical organelle for G2/M
checkpoint. Centrosome separation is initiated at the G2
phase and completed in the M phase. Several key proteins
involved in controlling the G2/M checkpoint have been
shown to physically associate with centrosome.
Centrosome-associated regulators of G2/M checkpoint
An increasingly number of cancer related proteins have
been shown to reside in or traffic in and out of centro-
somes. These regulators include: 1) A number of cell cycle-
regulated proteins, including cyclin B1, Cdks, Chks, Plks,
aurora kinases, and Neks [27-36]; 2) Oncogenes, such as
Survivin, Ras, Rad6, and HER2/neu [37-40]; 3) Tumor
suppressors including p53, Rb, p21, XRCC2/3, APC,
NM23-R1/H1, Gadd45 and BRCA l/2 [19,20,41-48]; and
4) Ubiquitination and degradation related proteins,
including anaphase-promoting complex/cyclosome
(APC/C), BRCA1, Cdc20, and Cdh1 [49-52]; 5) DNA
damage checkpoint proteins including ATM, ATR, p53,
BRCA1, Chk1, and Chk2 [29,53-59]. More detailed infor-
mation about these regulators is listed in Table 1. The
roles of these centrosome-associated regulators have been
extensively investigated and some of the current under-
standing of their roles in G2/M checkpoint and in
response to DNA damage is summarized in Fig 1. In this
section, we will review the regulatory roles of the key cen-
trosome-related kinases and some cancer related genes
involved in G2/M transition.
Cdc2 (also termed Cdk1) and its regulator cyclin B drive
cells into mitosis from G2 phase. In early G2 phase, Cdk1
is inactivated by phosphorylation of T14 and Y15 residues
by Wee1 and Myt1 kinases [60]. The initial activation of
cyclin B/Cdk1 occurs at the centrosome in prophase. This
involves Cdk1 dephosphorylation at T14 and Y15 by
Cdc25 phosphatase family (Cdc25A, B, and C) and cyclin
B phosphorylation at Ser126/128 by MPF and Ser133 by
Plk1 [61-65].
Chk1 and Chk2 are transducers of ATR- and ATM-depend-
ent signaling in response to DNA damage. Chk1 has been
detected at the interphase centrosome, and inhibition of
Chk1 resulted in premature centrosome separation [29].
Chk2 was also reported to localize to the centrosome and
could be phosphorylated at Thr 68/26 and Ser 28 by Plk1,
which co-localized with Chk2 at the centrosome in early
mitosis [66]. Chk1 is activated by ATR in cells treated with
ultraviolet radiation [67], whereas Chk2 is activated by
ATM in cells exposed to ionizing radiation [68]. Activa-
tion of ATM/ATR initiates the subsequent protein kinase
cascade through both p53 dependent and independent
pathways. In p53 dependent pathways, p53 is phosphor-
ylated on Ser 15 and Ser 20 [69-71] and then activates
downstream targets genes, such as p21 and 14-3-3, which
play an important role in G2/M checkpoint through inhi-
bition of Cdk1/cyclin B [72,73]. In the p53 independent
pathway, Chk1 and Chk2 phosphorylate Cdc25 at Ser
216, which down-regulate Cdc25 activity by promoting
14-3-3 protein and nuclear export [53,61]. Chk1/2 also
phosphorylates Wee 1 and increases Wee 1 activity. It is
known that both Cdc25C and Wee 1 phosphorylation
cooperatively reduce Cdk1/cyclin B1 activity leading to
G2/M arrest [61,74,75].
In mammalian cells, three members of the Aurora family
have been identified: Aurora A, B, and C. Among them,
Aurora A is associated with the centrosome and microtu-
bules. Aurora A is essential for controlling multiple steps
in the cell cycle from late S phase through M phase,
including centrosome maturation and separation, mitotic
spindle formation, and mitotic entry and exit. Aurora A
mediates its multiple functions by interacting with other
centrosome proteins including p53, centrosomin, centro-
mere protein A, Eg5, and BRCA1[76].
Plk1, which is the best studied member of the Plk family
in mammalian cells, is involved in various events in
mitotic progression [77]. Plk1 increases during S and G2/
M [78]. Plk1 phosphorylates and activates Cdc25, which
leads to activation of Cdk1/cyclin B1 and G2/M check-
point [79,80]. Plk1 also plays a role in mitosis exit by reg-
ulating the anaphase-promoting complex [81,82]. In
response to DNA damage, Plk1 activity is inhibited in an
ATM/ATR dependent manner [83], preventing mitosis
entry.
Nek2, which is a member of the Nek kinase family, has a
role in regulation of the G2/M checkpoint and is localized
to the centrosome. Nek2 has two splice variants: Nek2A
and Nek2B. Nek2A is required for centrosome separation
at the G2/M transition and forms a complex with the cat-
alytic subunit of protein phosphatase 1 (PP1) and a large
coiled-coil protein called C-Nap1 [84,85]. Nek2 can phos-
phorylate its substrates, C-Nap1 and Nlp, contributing to
their displacement from the centrosome, which is an
essential step for subsequent splitting of the centrosome
[85-87].
Survivin is a member of the inhibitor of apoptosis protein
(IAP) family that plays an essential role in the control ofMolecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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cell division and the inhibition of apoptosis [88]. Survivin
is expressed in a cell cycle-dependent manner and regu-
lates G2/M phase by localizing to multiple sites on the
mitotic apparatus including the centrosome, microtu-
bules, and the mitotic spindle [37]. Also, Survivin per-
forms its mitotic roles by cooperating with inner
centromere protein (INCENP) and Aurora B [89]. A basic
event for Survivin regulation is phosphorylation of the
Thr34 by the p34(Cdc2) kinase [90,91]. Survivin induces
apoptosis by inhibiting, directly or indirectly, the activity
of Caspases 3, 7, and 9.
Accumulating evidence indicates that BRCA1 is located in
the centrosome and binds to γ-tubulin [92]. BRCA1 has
an important role in regulating centrosome duplication.
This tumor suppressor is involved in all phases of the cell
Activation of the G2/M checkpoint after DNA damage Figure 1
Activation of the G2/M checkpoint after DNA damage. In response to DNA damage, the ATM, ATR signaling pathway 
is activated, which leads to the phosphorylation and activation of Chk1 and Chk2 and to the subsequent phosphorylation of 
Cdc25. Phosphorylated Cdc25 is sequestered in the cytoplasm by 14-3-3 proteins, which prevents activation of cyclinB/Cdk1 
by Cdc25 and results in G2 arrest. Activated ATM/ATR also activates p53-dependent signaling. This contributes to the mainte-
nance of G2 arrest by upregulating 14-3-3, which sequesters Cdk1 in the cytoplasm. In addition, p53 induces the transactiva-
tion of p21, a Cdk inhibitor that binds to and inhibits cyclinB/Cdk1 complexes. P: phosphorylation.Molecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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cycle and regulates orderly events during cell-cycle pro-
gression through its transcriptional activity and ubiquiti-
nation ligase E3 function [92-95]. BRCA1 interacts with
many proteins that play important roles in multiple bio-
logical pathways. These proteins include ATM, ATR,
Chk1/2, Wee1, p53, Aurora A, and Cdc25C [93,94,96,97],
all of which have important roles in G2/M cell cycle regu-
lation.
The ubiquitin-proteasome pathway (UPP) is essential for
degrading intracellular proteins, which plays a key role in
maintaining cellular homeostasis. Polymers of ubiquitin
are covalently attached to protein targets by three key
enzymes: ubiquitin-activating enzyme E1, ubiquitin-con-
jugating enzymes E2, and ubiquitin ligases E3. The result-
ing ubiquitinated proteins are then recognized and
degraded by the 26S proteasome [98]. Cyclin B/Cdk1 is a
master regulator during G2/M transition, and cyclin B/
Cdk1 activity is strictly governed by the anaphase-promot-
ing complex/cyclosome (APC/C), a ring-finger-type E3
that plays an important role in sister chromatid separation
and exit from mitosis by degrading mitotic substrates. The
APC/C is activated by its adaptor and regulators, such as
Cdc20 and Cdh1, to target Securin and mitotic cyclins.
Activation of APC/C is required for anaphase onset and
mitotic exit [99].
Dysregulation of the centrosome-associated regulators of 
G2/M checkpoint in cancer
Mounting evidence indicates that cell-cycle dysregulation
is a common feature of cancer. The G2/M checkpoint in
particular is an area of focus for cancer research. Abnor-
malities of several of above mentioned centrosome-asso-
ciated regulators of the G2/M checkpoint have been
detected in human tumors, as detailed below [21,100-
102]:
The Aurora A gene is located on chromosome 20q13.2, a
region that is commonly amplified in many epithelial
cancers. Both mRNA and protein levels of Aurora A are
overexpressed in a variety of tumor tissues and tumor cell
lines, suggesting its potential role in tumorigenesis.
Aurora A mRNA upregulation has been significantly asso-
ciated with advanced tumor stage, the presence of positive
regional lymph nodes, as well as distant metastasis in
head and neck squamous cell carcinoma [100]. Aurora A
also promotes cell migration and reduces the radiosensi-
tivity of laryngeal squamous cell carcinoma [103]. In
ovarian cancer, overexpression of Aurora A is associated
with centrosome amplification and poor survival [104].
Overexpression of Aurora A was significantly associated
with aggressive clinical behavior including high histologic
grade, invasion, metastasis and overall survival of patients
with bladder cancer. Aurora A gene copy number has been
reported to be a promising biomarker for detection of
bladder cancer [105,106].
Plk1 expression has been showed to be elevated in non-
small-cell lung, head and neck, esophageal, gastric, breast,
ovarian, endometrial, colorectal, and thyroid carcinomas;
melanomas, and gliomas [21]. Overexpression of Plk1
correlates positively with tumor stage, nodal status, and
diffuse growth pattern in human gastric cancer [107]. In a
study of 158 colon cancer patients, Weichert et al. found
that overexpression of Plk1 correlated positively with
Dukes stage and nodal status [108].
Overexpression of active Nek2A kinase leads to premature
splitting of the mother and daughter centrioles [18,109],
whereas expression of inactive Nek2A kinase causes the
formation of centrosomal abnormalities, monopolar
spindles, and aneuploidy [110], all of which are involved
in regulating genetic stability and tumorigenesis. Elevated
protein expression of Nek2 leads to centrosome abnor-
mality and, consequently, tumorigenesis. Nek2 expres-
sion is elevated in breast, ovary, cervical, prostate cancers,
and leukemia [101].
Abnormal expression of Survivin in mammalian cells
could result in aberrant mitotic progression characterized
by cell division defects that include supernumerary cen-
trosomes, mislocalization of mitotic kinases, and loss of
mitotic checkpoint. Survivin is overexpressed in a wide
spectrum of human cancer, including lung, breast, colon,
gastric, liver, bladder, uterine, and ovary cancer [102].
Heat-shock protein 90 (hsp90), a molecular chaperone,
plays a role in G2/M checkpoint regulation by associating
with its client proteins including Chk1, Cdk1, Wee1,
Myt1, Plk1, and cyclinB through regulation of their stabil-
ity. Hsp90 inhibitors could result in targeting of these cli-
ent proteins to the proteasome to be degraded which may
explain the substantial G2/M peak in cell cycle [111-114].
The APC/C, a multisubunit ubiquitin ligase E3, is a gate-
keeper for mitosis by balancing the amount of checkpoint
regulators. Two key activators for APC/C function are
Cdh1 and Cdc20. Dysfunction of APC/CCdh1 might result
in abnormal accumulation of both mitotic Cdk activity
and non-Cdk kinases activity(such as Aurora A, Plk, and
Nek2), leading to the development of cancer [115]. APC/
CCdc20 recognizes and marks the key substrate securin and
cyclin B1 for degradation and promotes chromosome sep-
aration and anaphase onset in a time- and spatial-depend-
ent manner. Deregulation of Cdc20-dependent
proteolysis can result in aneuploidy, ultimately resulting
in cancer. Securin has been reported to be overexpressed
in human breast and colorectal cancers [116,117]. In
addition, Hagting et al. found that blocked proteolysis ofMolecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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securin by APC/CCdc20 led to genomic instability in cul-
tured cells [50]. Thus, dysfunction of the APC/C might
lead to uncontrolled proliferation, genomic instability,
and cancer.
Modulation of G2/M checkpoint proteins and cancer 
therapy
Although there are defects in G2/M checkpoint proteins in
cancer, the nature of these alterations is quite different
from that of alterations of the G1/S checkpoint. The pres-
ence of p53 mutation in 50% of all cancers renders the G1/
S checkpoint less efficient, allowing synthesis of unre-
paired DNA [11,118]. For G2/M checkpoint proteins,
mutations of key players are not common. Even for
BRCA1, mutation is infrequent in sporadic cancers and
more concentrated in the familial breast cancers [94]. The
impact of p53 as a checkpoint protein is complex because
p53 is also a major regulator of apoptosis [119]. Because
cell cycle checkpoints also repair DNA damages caused by
therapeutics, the role of cell cycle checkpoints are often
the cause for resistance. On one hand, increased prolifer-
ation is a common feature for aggressive cancers, thus
inhibition of cell proliferation is a logical approach. On
the other hand, most cancer drugs target cycling cells, so
the fast growing tumor cells are more sensitive to these
treatments. It is well-known that slow-growing and more
differentiated cancers are generally resistant to chemo-
therapy. As a matter of fact, the G2/M checkpoint is invar-
iably activated in cancer cells in response to DNA damage
partially causing resistance to therapy [120,121]. Specifi-
cally, the G2/M checkpoint based anti-cancer strategies
have been focused on targeting and inactivating the G2/M
checkpoint, thus forcing the cancer cells into mitosis with
increased DNA damage and finally into mitotic catastro-
phe and cell death. Following is a brief review on some of
the checkpoint related cancer therapies under develop-
ment [122-127] (Table 2).
Table 2: Small molecule inhibitors targeting centrosome associated G2/M checkpoint regulators
Specific targets Functions Clinical development Combination with DNA-
damaging agents
Flavopiridol[128] Cdk1, p21, Survivin Bind to Cdc2, inhibit apoptosis Phase I/II paclitaxel, irinotecan, 
gemcitabine, IR
UCN-01[153-155] Cdk1, Chk1/2 Inhibit Chk1 and PKC activity, 
promote apoptosis
Phase I/II fluorouracil, topotecan, 
cisplatin, IR, temozolomide
Daidzein[139] Cdk1, p21Cip1, p57Kip2 Inhibit Cdk1 and cell proliferation Preclinical NA
Caffeine [123-125] ATM/ATR, PI3K Inhibit ATM/ATR, cause G2 
checkpoint abrogation, induce 
apoptosis
Phase I Taxol, cisplatin
KU-55933[122,126] ATM Inhibit ATM Phase I NA
Berberine[140,141] Wee1, 14-3-3, Cdk2, 
cyclinB, Cdc25c
Induce G2/M phase arrest and 
apoptosis
Preclinical NA
17AAG [145-147] Chk1, Hsp90 Downregulate Chk1, inhibit colony 
formation, induce apoptosis, 
abrogate G2/M checkpoint
Phase I/II gemcitabine, cisplatin, 
topoisomerase I poisons, 
taxol, IR
XL844[148] Chk1/2 Enhance gemcitabine antitumor 
activity
Phase I Gemcitabine
CHIR-124[149] Chk1 abrogate G2/M checkpoint, induce 
apoptosis
Preclinical Topoisomerase I poisons
PF-00477736[150] Chk1, cyclin B, Securin, 
Aurora
Inhibit Chk1, abrogates cell cycle 
arrest
Preclinical Gemcitabine, carboplatin
PD0166285[127] Wee1, Aurora A Inhibit Wee1, abrogate G2/M 
checkpoint
Preclinical NA
CEP-3891[143,151] Chk1 Abrogate G2/M checkpoint Preclinical IR
N-aryl-N'-pyrazinylurea 
[142,152]
Chk1 Inhibit Chk1, inhibit cell 
proliferation
Preclinical Doxorubicin, camptothecin
VX-680[166,170] Aurora A, B Block cell proliferation, disrupt 
bipolar spindle formation, 
accumulate of cell with 4N or 
greater DNA
Phase II Vorinostat, docetaxel
Hesperadin[171] Aurora kinase Inhibit Aurora kinase activity Phase I/II NA
ZM447439[173] Aurora A, B Inhibit Aurora A, induce apoptosis Phase I NA
PHA-739358[164] Aurora A, B, C Inhibit proliferation Phase I NA
PHA-680632 [167,163] Aurora A Inhibit Aurora A and proliferation Phase I IR
ON01910[179] Plk1, Cdk1 Inhibit Plk1, induce mitosis arrest Preclinical NA
Abbreviation: NA, not available; IR, ionizing radiationMolecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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Cdc2 inhibitors
To date, the majority of the published data suggests that
inhibition of cyclin/Cdk complexes may prevent or delay
tumor progression in cancer patients. Among a number of
Cdk inhibitors under development, flavopiridol and
UCN-01 are being tested in clinical trials [3,128]. We will
review flavopiridol as an example.
Flavopiridol binds and directly inhibits Cdc2 as well as
inhibiting antiapoptotic molecules including p21, Bcl2,
and Survivin [129-131]. Flavopiridol has been tested as a
novel chemotherapeutic agent for rhabdoid tumors, oste-
osarcoma, Ewing's family tumor cells, and leukemia [131-
133]. The combinations of flavopiridol with paclitaxel,
irinotecan, or gemcitabine have shown promising effects
in cell line studies and in clinical trials. It was reported
that paclitaxel or docetaxel followed by flavopiridol is
associated with an increased induction of apoptosis
through accelerating exit of cells from mitosis, but the
reverse treatment schedule did not show added effect than
paclitaxel or docetaxel alone [134-136]. Recently, it was
reported that paclitaxel treatment followed by carboplatin
for 1 hour and flavopiridol over 24 hours every 3 weeks
for 3 cycles was effective and safe in NSCLC patients
[137]. A greater antitumor effect was observed with the
combination of gemcitabine or irinotecan followed by fla-
vopiridol in several epithelial gastrointestinal cell lines
[129,138]. Thus, flavopiridol in combination with chem-
otherapy may overcome cell cycle mediated drug resist-
ance.
Other regulators of cyclin/Cdk complexes and Cdk inhib-
itors have been reported. Treatment with the isoflavone
daidzein decreased the expression of Cdc2 and increased
the expression of the Cdk inhibitors p21Cip1 and p57Kip2 in
MCF-7 and MDA-MB-453 cells. Thus, daidzein exerts its
anticancer effects in human breast cancer cells via cell-
cycle arrest [139]. Berberine has been reported to induce
G2/M arrest in leukemia and gastric cancer cells via the
inhibition of cyclin B1 and the promotion of Wee1
[140,141].
Chk1 inhibitors
There are a large reservoir of identified Chk1 inhibitors
including UCN-01, 17AAG, XL844, CHIR-124, PF-
00477736, CEP-3891, and N-aryl-N'-pyrazinylurea.
UCN-01, 17AAG, and XL844 are being tested in clinical
trials, while the others are still in preclinical studies [142-
152]. UCN-01 has been reported to promote apoptosis
through G2/M checkpoint abrogation in various human
cell lines. Thus, UCN-01 exerts more marked antitumor
effects through combination with radio- or chemotherapy
[153-155]. Results of three Phase I studies of combination
therapy with UCN-01 in patients with solid tumors have
been published, in which UCN-01 was combined with
fluorouracil [156], topotecan [157], and cisplatin [158],
respectively. UCN-01 plus topotecan or carboplatin were
found to be generally well tolerated; however, combina-
tion of UCN-01 and fluorouracil did not show significant
antitumor activity against advanced ovarian cancer
[159,160]. Further research to develop these combina-
tions is warranted, especially focusing on reducing side
effects.
Aurora Kinase Inhibitors
The evidence linking Aurora kinase overexpression and
malignancy has stimulated interest in identifying and
developing Aurora kinase inhibitors for cancer therapy.
RNA interference targeting Aurora A has been found to
suppress tumor growth and enhance sensitivity to chemo-
therapy- and radiation-induced apoptosis in human cells
[161,162]. Several Aurora kinase inhibitors, including VX-
680, Hesperadin, ZM447439, AT-9283, MLN-8054, R-
763, SU6668, and PHA-739358, have been identified and
are undergoing phase I/II clinical trials [163-167].
One of these inhibitors, VX-680, the first Aurora kinase
inhibitor to enter clinical trials, not only inhibits cell pro-
liferation but also induces apoptosis in a wide spectrum of
tumor types. VX-680 was shown to greatly inhibit tumor
growth  in vivo in three xenograft models of leukemia,
colon, and pancreatic tumors. It was reported that VX-680
has no effect on non-cycling normal cells which makes it
a promising anticancer agent [168]. VX-680 also was
found to be effective in reducing cell growth in different
anaplastic thyroid cancer-derived cell lines [169]. In ovar-
ian cancer, combination of VX-680 (also known as MK-
0457) with docetaxel could significantly reduce cell prolif-
eration and increase tumor cell apoptosis than VX-680 or
docetaxel alone in vivo [170]. Further investigation of this
inhibitor is warranted to exploit its potential value in the
treatment of cancer.
In tobacco BY-2 cells, another Aurora kinase inhibitor,
Hesperadin, was found to induce delayed transition from
metaphase to anaphase and early exit from mitosis after
chromosome segregation [171]. It is not clear, however,
whether Hesperadin causes tumor cell death. In a colony
formation assay, ZM447439, another Aurora kinase
inhibitor, was found to be more toxic to proliferating cells
than to nondividing cells [172], indicating that it might
also be used selectively to kill proliferating tumor cells.
ZM447439 is an effective apoptosis-inducing and G2/M
phase-arresting agent in acute myeloid leukemia and
Hep2 carcinoma cells [173,174].
Inhibitors of Plk1
The G2/M phase regulator Plk1 is frequently overex-
pressed in cancers and correlates with aggressiveness and
poor prognosis. Cogswell et al observed that silencing ofMolecular Cancer 2009, 8:8 http://www.molecular-cancer.com/content/8/1/8
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Plk1 functions induced apoptosis accompanied by
mitotic catastrophe in SAOS-2 and U-2OS tumor cells but
not in normal human mammary epithelial cells [175].
Findings from another study suggested that reduction of
Plk1 expression via small interfering RNAs (RNAi) could
prevent the growth of bladder cancer in vivo [176]. Down-
regulation of Plk-1 expression by RNAi has been found to
cause cell-cycle arrest at the G2/M phase, reduce cellular
proliferation, and increase gemcitabine cytotoxicity in
pancreatic tumor cells in vitro [177].
Small molecule inhibitors of Plk1 include ATP-competi-
tive and non-ATP-competitive categories. Identifying spe-
cific ATP-competitive inhibitors is challenging because of
the high degree of structural conservation among ATP-
binding domains in various kinases [178]. ON01910, a
non-ATP-competitive Plk1 inhibitor, was reported to
inhibit cancer cells growth by inducing mitosis arrest and
apoptosis in many tumor cell lines. Importantly,
ON01910 did not show hematotoxicity, liver damage, or
neurotoxicity in vivo [179]. Thus, ON01910 is a promising
Plk1 inhibitor that may exhibit beneficial effect in
patients.
Summary and future directions
Cell cycle checkpoints provide mechanisms for cells to
repair DNA damage. Activated checkpoints slow down
cell cycle progression and thus allow normal cells to repair
damage to prevent propagation of damaged DNA. The
development of anti-cancer therapeutics has capitalized
on the fact that activation of checkpoint proteins results in
attenuated cell proliferation lead to anti-growth cancer
therapeutics. Drugs have been developed to arrest cancer
cells and stop cancer cell proliferation. On the other hand,
the same mechanism that normally protects cells from
DNA damage also repairs DNA following chemotherapy
and radiotherapy. Therefore, strategies have been devel-
oped to abrogate the checkpoint activation, and drugs that
exert this effect are combined with chemo- or radiother-
apy to enhance cell kill.
In addition to small molecule inhibitors, gene based ther-
apeutics such as antisense oligonucleotides also show
promise. Recently, there is growing interest in a class of
small RNA termed microRNAs (miRNAs) [180]. The miR-
NAs are a class of small (~22 nucleotides) noncoding
RNAs that functions as post-transcriptional gene regula-
tors [181]. miRNAs may regulate the expression of many
genes, such as tumor-suppressor genes and oncogenes as
well as their molecular networks [182-186], which in turn
impact cell cycle progression [187,188]. miRNAs regulate
a wide range of biological processes, including cell differ-
entiation, proliferation, and apoptosis [189]. Aberrant
miRNAs expression is involved in human tumorigenesis
[190,191]. Mertens-Talcott et al [184] demonstrated that
miR-27a increased the percentage of MDA-MB-231 cells
in G2/M by inducing its target gene Myt-1, which inhibits
G2/M through enhanced phosphorylation and inactiva-
tion of Cdk1. Yang et al [185] showed miR-214 induces
cell survival and cisplatin resistance primarily by down-
regulation of PTEN protein and activation of the Akt path-
way through 3'-untranslated region (UTR) of the PTEN in
human ovarian cancer. According to Yang et al [192], let-
7i expression was significantly reduced in chemotherapy-
resistant epithelial ovarian cancer patients. The in vitro
study showed that reduced let-7i expression significantly
increased the resistance of ovarian and breast cancer cells
to cis-platinum. Thus, it was proposed that let-7i could be
targeted in platinum-resistance patients. Taken together,
miRNAs emerge as new therapeutic targets as well as tools
in cancer treatment.
Cancer stem cells (CSCs) have become a new focus in can-
cer research since they may play a role in cancer initiation,
metastasis, treatment resistance, and recurrence [193].
CSCs have been found in hematopoietic cancers as well as
solid tumors included brain, neck, lung, breast, liver,
colon, pancreas, prostate, bone, and melanoma [193-
199]. Investigations into characteristics of CSCs improved
our understanding of tumor treatment resistance. Con-
ventional chemo- or radiotherapies preferentially kill
dividing cells, but CSCs are low-growing, which make
them resistant to conventional therapy. It is also likely
that conventional therapies actually enrich CSCs and
these cells have to potential to repopulate. Therefore, fail-
ure to target CSCs predicts for cancer recurrence. Current
studies on CSCs zero in on the limitless proliferative
capacity, self-renewal pathways, drug efflux pumps, and
their niche [200]. Whether and how these features are
linked to cell cycle checkpoints are not clear although they
will likely be linked. The development of strategies that
target CSCs as well as checkpoint will likely crosses paths
and has potential in emergence in a new class of highly
effective cancer therapeutics.
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